Whitehawk Therapeutics Inc expected to post a loss of 46 cents a share - Earnings Preview

Whitehawk Therapeutics

02/05/2025 14:12

Whitehawk Therapeutics Inc WHWK.OQ WHWK.O is expected to show a fall in quarterly revenue when it reports  results on May 6 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Whitehawk Therapeutics Inc is for a loss of 46 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 44.3% in the last three months. ​

Wall Street's median 12-month price target for Whitehawk Therapeutics Inc is $2.00​, above​ its last closing price of $1.67. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.23
-0.22
-0.67
Missed
-204.5
Sep. 30 2024
-0.38
-0.46
-0.46
Met
-0.5
Jun. 30 2024
-0.69
-0.69
-0.54
Beat
21.7​
Mar. 31 2024
-0.63
-0.64
-0.68
Missed
-5.8
​​Dec. 31 2023
-0.65
-0.60
Beat
7.4
Sep. 30 2023
-0.72
-0.72
-0.60
Beat
17.1​
Jun. 30 2023
-0.61
-0.62
-0.67
Missed
-7.7
Mar. 31 2023
-0.58
-0.58
-0.57
Beat
2.4

This summary was machine generated May 2 at 13:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)